S&P 500   3,632.83 (+1.54%)
DOW   30,067.14 (+1.61%)
QQQ   293.33 (+1.01%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
S&P 500   3,632.83 (+1.54%)
DOW   30,067.14 (+1.61%)
QQQ   293.33 (+1.01%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
S&P 500   3,632.83 (+1.54%)
DOW   30,067.14 (+1.61%)
QQQ   293.33 (+1.01%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
S&P 500   3,632.83 (+1.54%)
DOW   30,067.14 (+1.61%)
QQQ   293.33 (+1.01%)
AAPL   114.91 (+0.93%)
MSFT   213.61 (+1.67%)
FB   274.29 (+2.18%)
GOOGL   1,754.55 (+1.56%)
AMZN   3,123.92 (+0.82%)
TSLA   546.78 (+4.78%)
NVDA   518.71 (-1.31%)
BABA   277.33 (+2.67%)
CGC   26.95 (+9.02%)
GE   10.56 (+4.87%)
MU   63.02 (-1.81%)
AMD   84.64 (-0.79%)
T   29.26 (+2.24%)
NIO   52.99 (-4.32%)
F   9.43 (+6.43%)
ACB   9.08 (+26.46%)
NFLX   482.24 (+1.18%)
GILD   60.89 (+1.67%)
BA   220.33 (+4.16%)
DIS   151.58 (+3.84%)
Log in
OTCMKTS:GNWSF

StageZero Life Sciences Stock Forecast, Price & News

$0.53
+0.03 (+6.00 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.53
Now: $0.53▼
$0.53
50-Day Range
$0.50
MA: $0.60▼
$0.66
52-Week Range
$0.17
Now: $0.53▼
$0.89
Volume4,600 shs
Average Volume5,468 shs
Market Capitalization$26.56 million
P/E RatioN/A
Dividend YieldN/A
Beta3.35
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNWSF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.stagezerolifesciences.com
Phone905-209-2030
Employees16

Debt

Debt-to-Equity RatioN/A
Current Ratio0.09
Quick Ratio0.06

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$140,000.00
Price / Sales189.75
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.13) per share
Price / Book-4.08

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-3,480,000.00
Net Margins217.39%
Return on EquityN/A
Return on Assets-61.21%

Miscellaneous

Outstanding Shares50,103,000
Market Cap$26.56 million
Next Earnings Date5/19/2021 (Estimated)
OptionableNot Optionable
$0.53
+0.03 (+6.00 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNWSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNWSF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











StageZero Life Sciences (OTCMKTS:GNWSF) Frequently Asked Questions

How has StageZero Life Sciences' stock price been impacted by COVID-19 (Coronavirus)?

StageZero Life Sciences' stock was trading at $0.0266 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNWSF shares have increased by 1,893.2% and is now trading at $0.5302.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than StageZero Life Sciences?

Wall Street analysts have given StageZero Life Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but StageZero Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is StageZero Life Sciences' next earnings date?

StageZero Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for StageZero Life Sciences.

Are investors shorting StageZero Life Sciences?

StageZero Life Sciences saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 51,000 shares, an increase of 59.4% from the October 15th total of 32,000 shares. Based on an average trading volume of 9,100 shares, the days-to-cover ratio is presently 5.6 days.
View StageZero Life Sciences' Short Interest.

Who are some of StageZero Life Sciences' key competitors?

Some companies that are related to StageZero Life Sciences include OncoCyte (OCX), Trinity Biotech (TRIB), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), ImmuCell (ICCC), ARCA biopharma (ABIO), Achieve Life Sciences (ACHV), StageZero Life Sciences (GNWSD), Akers Biosciences (AKER), BG Medicine (BGMD), Response Genetics (RGDXQ), Fuse Science (DROP) and FluoroPharma Medical (FPMI).
View all competitors.

Who are StageZero Life Sciences' key executives?

StageZero Life Sciences' management team includes the following people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Mr. Carl Solomon, Interim Chief Financial Officer
  • Prof. Choong-Chin Liew, Co-Founder
  • Mr. Warren Whitehead C.M.A., Chief Accountant (Age 68)
  • Mr. David Suria, Sr. Scientist

What is StageZero Life Sciences' stock symbol?

StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "GNWSF."

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is StageZero Life Sciences' stock price today?

One share of GNWSF stock can currently be purchased for approximately $0.53.

How big of a company is StageZero Life Sciences?

StageZero Life Sciences has a market capitalization of $26.56 million and generates $140,000.00 in revenue each year. StageZero Life Sciences employs 16 workers across the globe.

What is StageZero Life Sciences' official website?

The official website for StageZero Life Sciences is www.stagezerolifesciences.com.

How can I contact StageZero Life Sciences?

StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.